Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

News Daily News

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

June 06, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

February 26, 2025

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

April 12, 2024

Bempedoic Acid Gains CV Risk Reduction Indication

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

March 22, 2024

Injectable Semaglutide Shortage Forces Physicians to Pivot

News Daily News

Injectable Semaglutide Shortage Forces Physicians to Pivot

February 05, 2024

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

January 12, 2024

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms

News Daily News

VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms

May 06, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.